Figure 6
From: MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7
miR-17-5p modulates Smad7 expression and is increased in serum of patients with liver cirrhosis. (a) Suppression of Smad7 protein by TGF-β1 was restored by miR-17-5p inhibitor. β-actin was used as the internal control for western blot analysis. (b) Suppression of Smad7 mRNA expression by TGF-β1 was restored by miR-17-5p inhibitor. Each value represents the mean±s.d. of three experiments. *P<0.05, compared with the control. #P<0.05, compared with the TGF-β1 group. (c) Serum levels of miR-17-5p were significantly higher in patients with cirrhosis, compared to healthy controls (P<0.0001).
